CURIS INC
CRISNext catalyst
Data Readout — zanubrutinib
Get an email about CRIS's next catalysts
Track CURIS (CRIS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (earnings, data readout, Phase 2 readout).See the timeline
4 upcoming, 2 past
CRIS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-2.29 | FQ end Sep/2026 | Call: tbd
Data Readout — zanubrutinib
For chronic lymphocytic leukemia. Curis announced eleven active clinical sites for the TakeAim CLL combination study with zanubrutinib and reaffirmed guidance for dosing five initial patients by July 2026 with data expected in December 2026. Stockholders also approved a reverse stock split.
SourceData Readout — zanubrutinib
For chronic lymphocytic leukemia. Curis announced eleven active clinical sites for the TakeAim CLL combination study with zanubrutinib and reaffirmed guidance for dosing five initial patients by July 2026 with data expected in December 2026. Stockholders also approved a reverse stock split.
SourceEmavusertib Phase 2 Est. Readout
Estimated primary completion for Emavusertib trial (NCT03328078) in Relapsed Hematologic Malignancy. Topline data typically follows completion by weeks to months.
SourceHow CRIS's past catalysts played out
Market Overview
Stock performance and key metrics
CUDC-907
Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Emavusertib
Acute Myelogenous Leukemia
Zanubrutinib
Chronic Lymphocytic Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CUDC-907 | Phase 2 | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | - | - |
Emavusertib | Phase 2 | Acute Myelogenous Leukemia | - | - |
Zanubrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Frequently asked questions
What is in CURIS INC's drug pipeline?→
CatalystAlert tracks 3 drug candidates in CURIS INC's (CRIS) pipeline across Phase 2. Its lead program is Emavusertib (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CURIS INC's next FDA catalyst?→
CURIS INC's (CRIS) next tracked catalyst is a data readout expected Dec 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CRIS biotech catalysts?→
Add CRIS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CURIS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.